The assay of oestrogen receptor (ER) has become a routine procedure in the clinical evaluation of breast cancer (Byar et al., 1979; Allegra et al., 1980) . Along with ER, the presence of progesterone receptor (PR) (Clark et al., 1983; AlexievaFigusch et al., 1988 ) and pS2 protein (Rio et al., 1987; Henry et al., 1991; Predine et al., 1992) is considered to reflect a functional mechanism by which the tumour cells are able to respond to oestrogen stimulation. Like PR and pS2, cathepsin D synthesis is also controlled by oestrogen in the human breast cancer cell line MCF-7 (Westley & Rochefort, 1980; Rochefort et al., 1987) . However, both cathepsin D and pS2 are also released as constitutive products in hormoneindependent systems. Thus, pS2 has been immunohistochemically detected in the stomach mucosa of healthy subjects (Rio et al., 1988a) , while cathepsin D has been found in ER-negative cell lines (Westley & Rochefort, 1980) . Clinically, pS2 can be considered an additional marker of hormone sensitivity, while cathepsin D in some studies appeared to have powerful predictive values (Spyratos et al., 1989; Thorpe et al., 1989; Tandon et al., 1990; Kute et al., 1992) , although in others it did not (Henry et al., 1990; Janicke et al., 1993) . Similarly, many studies have suggested that cathepsin D may have a role in tumour progression and invasiveness (Rochefort, 1992) , but others have shown strongly contrasting results (Johnson et al., 1993; Ravdin, 1993) . The physiological role of pS2 is still unclear. Nevertheless, pS2 shows a high degree of homology with the two insulin-like growth factors, IGFI and IGFII (Rio et al., 1988b) ; interestingly, cathepsin D can bind to the IGFII receptor, modulating its growth stimulatory action (Mathieu et al., 1990 Immunoradiometric assay ofpS2 and cathepsin D pS2 and total cathepsin D assay were performed by solidphase two-site immunoradiometric assays according to the instructions provided with the CIS Biointernational Kits (Gif-Sur-Yvette, France). Both systems have been validated by others (Garcia et al., 1985; Goussard et al., 1991) and used for pS2 and total cathepsin D assay by many research groups (Spyratos et al., 1989; Brouillet et al., 1990; Goussard et al., 1991; Marsigliante et al., 1992) .
Receptor assays For routine steroid-binding assays of ER and PR with the dextran-coated charcoal (DCC) method, procedures were used exactly as recommended by the EORTC Breast Cancer Cooperative Group (1980) . Values between 3 and 20 fmol mg-' protein have commonly been used as a cut-off point for classifying a receptor as positive or negative. A value of 10 fmol mg-' protein is used in the majority of studies (Parl et al., 1984; Alanko et al., 1985) and in the present one.
Protein estimation Protein estimation was carried out using the method of Bradford (1976) using bovine serum albumin (BSA) as the standard.
Results
Data obtained by both centres were not significantly different as assessed by using the non-parametric Mann-WhitneyWilcoxon's rank-sum test (MWW) (P>0.5); data were therefore combined to gain a single population for further analyses. Spearman's rank correlation between ER and PR was rs= 0.41 (P <0.0001). No significant differences in the expression of ER and PR taken from N + and N -patients were found (MWW: P>0.2). pS2 expression pS2 content ranged from 0 to 182 ng mg-' protein (mean± s.d. 21.2 ± 2, median 5.0). pS2 concentration did not vary significantly between lymph node-positive and -negative patients (MWW: P> 0.5). There were no significant differences in pS2 expression by stratifying tumours on the basis of their size (T) by using Kruskal-Wallis one-way analysis (P = 0.33).
Associations between pS2 and steroid receptor status Tumours expressing ER had higher levels of pS2 than those which did not (MWW: P = 3 x 10-10) ( Figure 1 ). pS2 was also quantitatively associated with the expression of ER and PR, in that rank correlation by Spearman's gave rs = 0.38, P<0.0001, and rs = 0.29, P = 0.022, respectively. pS2 values in tumours coexpressing both receptors (ER+/ PR+, n = 126) were significantly higher than those found in either the remaining ones (n = 140) (MWW: P = 2 x 10-10) ( Figure 1 pS2High, n = 82) (PS2High = pS2 values above the median: 5 ng mg 1) appeared to have higher levels of cathepsin D than those which were negative for at least one protein (MWW test: P = 2 x 10-5) and than those which expressed none of them (ER-/PR-/pS2LO,W n = 44, MWW: P = 4 x 10-'). The stratification of cathepsin D in some of these subgroups is shown in Figure 3 . No significant differences in cathepsin D concentration were found between samples taken from lymph node-positive and lymph node-negative patients (MWW: P>0.05). Furthermore, no significant differences in the expression of cathepsin D were obtained by stratifying tumours on the basis of their size (Kruskal-Wallis: P = 0.1).
Associations between pS2 and total cathepsin D Tumours were divided in two subgroups of equal size (n = 133) differing for pS2 value (pS2 above and below the median) and a stratification of cathepsin D was therefore obtained; tumours expressing pS2> 5 ng mg' protein (pS2High) had significantly higher level of cathepsin D than tumours expressing less than 5 ng mg' protein pS2 (pS2LOW) (MWW: P = 0.00001) (Figure 3) . Multiple linear regression analysis performed between cathepsin D (treated as the dependent variable) and the logarithmic transformation of the independent variables ER, PR and pS2 (the distributions of these parameter levels were highly skewed and the quantitative values expressed as logarithms are nearer to normality) indicated that pS2 was the most important variable and the better predictor in cathepsin D determination. Spearman's rank correlation between pS2 and cathepsin D concentration values was weak (rs = 0.21) but highly significant (P<0.0001). Non-parametric correlations were also performed after dividing the patients into N+ and N-; while in 1982). We confirmed a strict relationship between pS2 and both ER and PR (Figures 1 and 2) (Rio et al., 1987; Foekens et al., 1990; Goussard et al., 1991; Henry et al., 1991; Cappelletti et al., 1992; Koerner et al., 1992; Predine et al., 1992) , and showed that pS2 values are actually higher in those tumours having both ER and PR than in the remaining ones.
The most remarkable finding seems to be the relationship between cathepsin D and pS2 values (Figures 3 and 4) . This is supported by the multiple linear regression indicating that the effects of ER and PR on cathepsin D expression are quite marginal relative to the effects provoked by the pS2 protein.
Unfortunately this attempt to disentangle and measure the effects of ER, PR and pS2 on cathepsin D is limited by the fact that the three independent variables are highly interrelated. More feasible analysis can however be obtained stratifying tumours by the pS2 median value and applying tests for significance levels. In this way, it can be shown that tumours having more than 5 ng mg-' protein pS2 expressed higher levels of cathepsin D than the tumours having pS2 less than 5 ng mg-' protein ( Figure 3) . However, at least one bias is inherent in this analysis because of the arbitrary cut-off chosen. A further analysis independent of cut-off points also showed interrelationship between the two variables ( Figure  4) . Interestingly, it can be seen that, in patients with positive lymph nodes, a significantly higher correlation between pS2 and total cathepsin D occurred than in the N-patients (P<0.0001 and P>0.05 respectively). This relation between pS2 and cath*psin D could be explained by the hypothesis that a direct control of pS2 on total cathepsin D expression exists in breast cancer, especially in lymph node-positive patients. This hypothesis may provide an explanation for the observed up-regulation of both pS2 and cathepsin D in ER-positive breast cancer cell lines following oestradiol administration (Cavailles et al., 1989) . Obviously, the major driving force in the whole machinery would remain the oestrogen receptor and its functionality, a functional ER being able to bind steroid and thereafter initiate transcription of oestrogen-regulated proteins, including PR and pS2. At this stage, pS2 might function as a growth factor perhaps able to interact by paracrine mechanisms with other cells (also nonresponsive to the oestrogen) and to facilitate lymph node metastasis through the expression of cathepsin D. The involvement of both ER+ and ER-tumour cells by pS2 paracrine mechanisms, amplifying the oestrogen signal, may account for the lack of correlation between cathepsin D and ER values in breast cancer biopsies. In this study, tumours expressing both steroid receptors and high pS2 concentrations had higher cathepsin D levels (Figure 3) , a status suggestive of intact, functional oestrogen receptor machinery. Adjuvant hormone therapy, by antagonising oestrogenmediated induction of pS2, would be expected to present cathepsin D up-regulation in such tumours.
ER has been used as a predictor of prognosis and response to endocrine therapy in breast cancer patients. Moreover, determination of the PR concentration is of equal or greater value than determination of the ER concentration for predicting the disease-free survival of patients and response to endocrine treatment (Clark et al., 1983) ; however, the ER+/ PR+ status appears to be the best prognostic factor for assessing response (Fisher et al., 1983; Alanko et al., 1985; Alexieva-Figusch et al., 1988) . Conversely, pS2's role in predicting prognosis is contradictory (Foekens et al., 1990; Henry et al., 1991; Cappelletti et al., 1992; Predine et al., 1992) , but it seems to be associated with a response to hormonal therapy (Schwartz et al., 1991) . Clearly, the determination of the pS2 values in patients whose tumours express only one of the two sex steroid receptors could help in the prediction of response to hormonal therapy. We found that 36/266 (13.5%) tumours were ER-/PR+ and that 50/266 (18.8%) tumours were ER+/PR-; both groups contained high levels of pS2, with concentration similar to those found in the ER+/PR+ group (Figure 2) . Here, the presence of pS2 would guarantee also the presence of an ER able to activate transcription, but such information should be also associated with the saturation analysis of ER, if one wishes to ascertain its ligand-dependent nature. The ER-/PR + tumours derived mainly from premenopausal patients ( Figure  5 ) whose tumours could well contain high circulating steroid levels and therefore endogenous hormone-filled receptors (Seriff & Durant, 1981) , not assayable by steroid-binding methods. Conversely, 30 out of 50 ER+/PR-patients were post-menopausal ( Figure 5 ). Here, one may wish to determine if such ER is non-functional (as aberrant receptor forms exist which bind ligand but are unable to activate transcription; Sherman et al., 1978; Rusconi & Yamamoto, 1987) , or whether it is still a biologically active liganddependent system which can be 'switched off by classical anti-oestrogens such as tamoxifen. Clearly, the presence of both PR and pS2 is a strong indicator of endocrine responsiveness.
In conclusion, we have shown that, in breast tumour cytosols, a relationship between pS2 and total cathepsin D exists which could point to a possible role of pS2 in cathepsin D overexpression. Also, pS2 can be conveniently used in the determination of a functional ER.
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